News | May 23, 2025
Venus Remedies secures Ukrainian GMP renewal
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Subscribe To Our Newsletter & Stay Updated
